54149-39-2

Basic information

• Product Name: Tpc-A014
• Synonyms: o-(2-Methoxy-ethyl)-hydroxylamine;Tpc-A014
• CAS NO: 54149-39-2
• Molecular Formula: C₃H₉NO₂
• Molecular Weight: 91.1091
• Mol File: 54149-39-2.mol

Chemical Properties

• Boiling Point: 157.476°C at 760 mmHg
• Flash Point: 61.051°C
• Appearance: /
• Density: 0.965g/cm³
• Vapor Pressure: 2.749mmHg at 25°C
• Refractive Index: 1.401
• Storage Temp.: Refrigerator, Under inert atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 4.27±0.70(Predicted)
• CAS DataBase Reference: Tpc-A014(CAS DataBase Reference)
• NIST Chemistry Reference: Tpc-A014(54149-39-2)
• EPA Substance Registry System: Tpc-A014(54149-39-2)

Safety Data

• Hazardous Substances Data: 54149-39-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tpc-A014 is used as an antagonist for the adenosine A2a receptor to treat diseases or conditions in which the adenosine A2a receptor activity is implicated. By blocking the receptor, Tpc-A014 can potentially alleviate symptoms and improve patient outcomes in various therapeutic areas.

InChI:InChI=1/C3H9NO2/c1-5-2-3-6-4/h2-4H2,1H3

Upstream product

• 54149-18-7 2-(2-Methoxy-ethoxy)-isoindole-1,3-dione 

Downstream Products

• 1443102-65-5 4-((3aS,7aS)-3-(4-cyano-3-(trifluoromethyl)phenyl)-2-oxooctahydro-1H-benzo[d]imidazol-1-yl)-2-fluoro-N-(2-methoxyethoxy)benzamide 
• 1177368-31-8 (E)-2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one O-2-methoxyethyloxime 
• 1091608-25-1 C₄₀H₄₅N₃O₇Si 
• 1032818-72-6 (2-methoxyethoxy)-carbamic acid 4-nitro-phenyl ester 
• 41776-68-5 3-Formylrifamycin SV-O-Methoxyaethylenoxim 
• 55634-46-3 2-[1-(2-Methoxy-ethoxyamino)-propylidene]-5,5-dimethyl-cyclohexane-1,3-dione 

Relevant articles and documents

Radical C(sp3)-H Heck-type Reaction of N-Alkoxybenzimidoyl Chlorides with Styrenes to Construct Alkenols

We report the first radical C(sp3)-H Heck-type reaction of aliphatic alcohols for selective δ- and ?-alkenol synthesis by photoredox catalysis. N-Alkoxybenzimidoyl chlorides are developed as novel alkoxyl radical precursors with tunable redox potentials. Various alkenols can be constructed by the inert C(sp3)-H Heck-type reaction of 4-cyano-N-alkoxybenzimidoyl chlorides with styrene derivatives under redox-neutral conditions, which can be performed on the gram scale and can be easily derivatized.

HMOX1 inducers

The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.

OXIM DERIVATIVES AS HSP90 INHIBITORS

The invention relates to HSP90 inhibiting compounds consisting of the formula: (I) wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

CHEMOKINE RECEPTOR BINDING COMPOUNDS

Compounds that modulate the activity of chemokine receptors, in particular CCR5, are disclosed.

CHEMOKINE RECEPTOR BINDING COMPOUNDS

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. Thesd compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids

The present invention relates to oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof. The present invention also relates to crystaline forms of oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.

N3 alkylated benzimidazole derivatives as MEK inhibitors

Disclosed are compounds of the formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.

Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6- (arylthio)uracils

A series of 1-alkoxy-5-alkyl-6-(arylthio)uracils was synthesized and tested for their ability to inhibit HIV-1 replication. Treatment of 2-alkyl- 3,3-bis(methylthio)acryloyl chlorides (5a-e) with AgOCN in benzene followed by reaction of the resulting isocyanates 6a-e with an appropriate alkoxyamine gave N-alkoxy-N'-((2-alkyl-3,3-bis(methylthio)acryloyl)ureas (10a-z) in good to excellent yields. Cyclization of 10a-z in AcOH containing a catalytic amount of p-TsOH produced 1-alkoxy-5-alkyl-6-(methylthio)uracils (11a-z). Oxidation of 11a-z with 3-chloroperoxybenzoic acid in CH2Cl2 resulted in high yields of 1-alkoxy-5-alkyl-6-(methylsulfonyl)uracils (12a-x and 12z) and 1-(benzyloxy)-6-(methylsulfinyl)thymine (12y), which were subsequently reacted with an appropriate arenethiol in ethanolic NaOH solution to afford 1-alkoxy-5-alkyl-6-(arylthio)uracils (14-49). Substitution at the 3- and 5- positions of the C-6-(phenylthio) ring by two methyl groups significantly increased its original anti-HIV-1 activity (EC50: 6-((3,5- dimethylphenyl)thio)-5-isopropyl-1-propoxyuracil (18), 0.064 μM; 6-((3,5- dimethylphenyl)thio)-1-(3-hydroxypropoxy)-5-isopropyluracil (23), 0.19 μM). Among the various alkoxy substituents at the N-1, the propoxy group was the most beneficial for improving the anti-HIV-1 activity. The 1-propoxy derivative 18 proved to be the most potent inhibitor of HIV-1 replication, followed by the 1-(3-hydroxypropoxy) derivative 23. Introduction of an isopropyl group at C-5 of the uracil base also remarkably enhanced the activity. When compound 18 was incubated with a rat liver homogenate preparation, no metabolite was observed, thus confirming the metabolic stability of the N-O bond in these 1-alkoxyuracils.